Effects of rituximab and dexamethasone on regulatory and proinflammatory B‐cell subsets in patients with primary immune thrombocytopenia

Publisher： John Wiley & Sons Inc

E-ISSN： 1600-0609|100|1|45-52

ISSN： 0902-4441

Source： EUROPEAN JOURNAL OF HAEMATOLOGY, Vol.100, Iss.1, 2018-01, pp. : 45-52

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rituximab, Ara-C, Dexamethasone and Oxaliplatin Is Safe and Active in Heavily Pretreated Patients with Diffuse Large B-Cell Lymphoma

By  

Oncology, Vol. 69, Iss. 6, 2006-02 ,pp. : 499-502

Karger

Access to resources Recommend Favorite

Need for an improved vaccination rate in primary immune thrombocytopenia patients exposed to rituximab or splenectomy. A nationwide population‐based study in France

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 4, 2015-04 ,pp. : 301-305

John Wiley & Sons Inc

Access to resources Recommend Favorite

Rituximab in Previously Treated Primary Immune Thrombocytopenia Patients: Evaluation of Short- and Long-Term Efficacy and Safety

By  

Acta Haematologica, Vol. 132, Iss. 1, 2013-12 ,pp. : 24-29

Karger

Access to resources Recommend Favorite

Depression in adult patients with primary immune thrombocytopenia

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 91, Iss. 10, 2016-10 ,pp. : E462-E463

John Wiley & Sons Inc

Access to resources Recommend Favorite

Role of radiation therapy in primary mediastinal large B‐cell lymphoma in rituximab era: A US population‐based analysis

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 11, 2015-11 ,pp. : 1052-1054

John Wiley & Sons Inc

Access to resources Recommend Favorite